DOCSLIB.ORG

Cisapride: a Novel Gastroprokinetic Drug V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cisapride: a Novel Gastroprokinetic Drug V The Canadian Journal of Hospital Pharmacy - Volume 44, No. 4, August, 1991 175 Cisapride: A Novel Gastroprokinetic Drug V. Arora and M. Spino ABSTRACT RESUME Impaired gastrointestinal motility underlies a multitude of Une motilite gastro-intestinale pathologique est le signe digestive complaints. Metoclopramide, an antidopaminer­ d 'une multitude de maladies digestives. Le metoclopramide, gic and cholinomimetic agen~ was the first prokinetic drug un agent anti-dopaminergique et cholinomimetique, fut le used to treat such conditions, but a high incidence of premier medicament procinetique utilise pour traiter de adverse effects has limited its use, especially in infants. tel/es conditions mais une frequence elevee des reactions Domperidone, the second prokinetic drug marketed in indesirables a limite son usage, surtout chez !es nourrissons. Canada, is a potent peripheral dopamine receptor an­ Le domperidone, le deuxieme medicament procinetique tagonist which does not cross the blood-brain barrier well commercialise au Canada, est un antagoniste puissant des and, therefore, displays minimal CNS side effects. Cisapride recepteurs dopaminergiques peripheriques qui ne traverse is a gastroprokinetic agent which appears to act mainly pas beaucoup la barriere hemo-encephalique et done, by releasing acetylcholine from the myenteric plexus of provoque peu d'effets secondaires au systeme nerveux the gut. It has no dopamine-blocking activity, and does central (SNC). Le cisapride est un nouvel agent gastro­ not share the serious CNS side effects of other drugs in procinetique qui semble agir principalement par la libe­ its class. These drugs stimulate gastric and small intestinal ration de l'acetylcholine du plexus myenterique de l'intestin. activity, but cisapride also enhances colonic motility. ll ne bloque pas la dopamine, done n 'apporte aucun effet Cisapride is well tolerated, and seems to exhibit a more secondaire serieux au SNC. Ces medicaments stimulent favourable benefit.'risk ratio than metoclopramide or la motilite gastrique et celle de l'intestin grele, mais en domperidone. Further studies will detennine the relative plus, le cisapride augmente la motilite du colon. Le cisapride place ofcisapride in the treatment of GI motility disorders. est bien to/ere et semb/e posseder un rapport avantage: Key Words: cisapride, domperidone, metoclopramide, risque plus favorable que le metoclopramide et le dompe­ prokinetic drugs ridone. D'autres etudes detennineront la place respective du cisapride dans le traitement des troubles de la motilite GI (gastro-intestinale). Mots des: cisapride, domperidone, metoclopramide, pro­ Can J Hosp Pharm 1991; 4: 175-181 cinetique medicament INTRODUCTION sympathetic, parasympathetic and is widely used as an antiemetic and Impaired gastrointestinal (GI) mo­ enteric nervous systems. Input GI motility modifierl.3. Domperi­ tility underlies a multitude of di­ from these systems is modulated done has been on the Canadian gestive complaints including de­ by the central nervous system market for several years, although layed gastric emptying and gastro­ which regulates GI motility2. Cho­ it is still an investigational drug in esophageal reflux. Patients suffer­ linomimetics are a logical choice the United States4. It acts primarily ing from such conditions may for the treatment of GI motility as a peripheral dopamine receptor benefit from enhanced GI motility. disorders since GI motility is lar­ antagonist, and has a lower poten­ The pathophysiology of GI motility gely controlled by cholinergic tial for extrapyramidal side effects. disorders normally involves neural mechanisms. Most agents used, es­ Cisapride is a novel prokinetic rather than primary muscular dis­ pecially for gastroesophageal re­ agent which was developed by turbances. Therapeutically diverse flux (GER), either potentiate the Janssen Pharmaceutica to target pharmacologic and non-pharma­ action of acetylcholine or block effects on the GI system only. Stu­ cologic modalities have been used dopamine receptors. dies indicate that cisapride mod­ in the treatment of such disorders 1• Metoclopramide, an antidopa­ ifies motility along the entire GI The GI tract is innervated by the minergic and cholinomimetic drug, tract5- 10. V. Arora, B.Sc.Phm., is a Staff Phamiacist, Sunnybrook Health Science Centre. M. Spino, Pharrn.D., is a Professor, Faculties of Pharmacy and Medicine, University of Toronto, and Senior Scientist, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario. Address correspondence to: V. Arora, K Wing Pharmacy, Sunnybrook Health Science Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5. 176 The Canadian Journal of Hospital Phannacy Volume 44, No. 4, August, 1991 Pharmacology reduced in patients with impaired matic hydroxylation. The pharma­ Cisapride has a unique mechanism gastric emptying1,2,7• Cisapride has cological activity of the metabo­ of action. It is not an antidopami­ an absolute bioavailability of 40 to lites is negligible compared to the nergic or a cholinergic agent9,11 but 50% and undergoes an extensive parent compound. Cisapride and is believed to indirectly enhance first pass metabolism 14. Domperi­ its metabolites are equally excreted the release of acetylcholine by done is also subject to a large first in urine and feces. About 41 to 45% stimulating receptors located on pass effect with only about 15% of a single dose is eliminated as the postganglionic neurons of the of an oral dose reaching the sys­ norcisapride. Less than 1% and myenteric (Auerbach's) plexus of temic circulation. Bioavailability 4-6% of the parent drug is nor­ the gut. This results in stimulation of metoclopramide is extremely mally eliminated in urine and feces, of cholinergic (muscarinic) recep­ variable with reports of 30 to 100% respectively3,6. tors on smooth muscle cells of the of an oral dose reaching the sys­ Metoclopramide has a high first­ gut. There is also some evidence temic circulation as unchanged pass effect. It is conjugated with that cisapride acts as an antagonist drug1,2,1s_ sulfuric acid or glucuronic acid. of serotonin (5-hydroxytrypta­ After oral administration of a Approximately 85% of an oral mine) receptors, however, the clin­ single 10 mg dose, peak plasma dose appears in the urine as parent ical significance of this effect re­ concentrations are reached within drug and conjugates, and 5% is mains to be determinedJ,s,12_ one to two hours for all three drugs. excreted in the feces via bile. Five Metoclopramide's mechanisms Maximal plasma levels obtained to 10% of an oral dose appears in of action is complex. This procai­ are about 45 to 65 µg/L with cisa­ the urine as a metabolite with un­ namide derivative blocks peri­ pride, 30 to 45 µg/L with meto­ determined pharmacological ac­ pheral and central dopaminergic clopramide and 20 µg/L with tivity. In total, about 20% of the receptors, including those at the domperidone. Co-administration drug is excreted unchanged1,11_ vomiting centre. It also has peri­ with food increases the extent of Domperidone undergoes hydro­ pheral cholinergic and direct drug absorption with the Cmax xylation and oxidative N-dealky­ smooth muscle activity 13. Effects about 20% higher after a meal 1,2,6. lation to inactive metabolites ex­ on GI motility are mediated Distribution: In adults, cisapride creted in the urine and feces. Less through enhanced acetylcholine and metoclopramide have compar­ than 5% of a dose is excreted in release from postganglionic neu­ able apparent volumes of distri­ the urine unchanged, although rons in the gut, and sensitization bution: 2.4 L/kg and 2.2 to 3.4 L/ about 30% appears as glucuronide of cholinergic (muscarinic) recep­ kg, respectively. Domperidone's conjugates of the two principle tors of GI smooth muscle to ace­ apparent volume of distribution is metabolites. These metabolites are tylcholine. Metoclopramide re­ about 5 to 6 L/kg. Plasma protein mainly excreted in the feces2. quires inherent neuronal acetyl­ binding is very high for cisapride Cisapride has a terminal half­ choline storage sites to exert phy­ and domperidone at >90% while life of about 15 hours. The half­ siologic release of this neurotrans­ only 25 to 30% of metoclopramide life may be prolonged in some mitter1. is bound1,2,6,14. elderly patients and in those with Although domperidone is struc­ Domperidone has high affinity impaired hepatic function. This turally similar to the butyrophe­ for dopamine receptors. It does not might be expected since cisapride none compounds, it does not cross cross the blood-brain barrier ex­ is mainly eliminated via hepatic the blood-brain barrier well and, tensively but does act at the che­ oxidation. Renal insufficiency does therefore, is not used as a neuro­ moreceptor trigger zone (CTZ) to not appear to significantly affect Ieptic. In vitro, domperidone has inhibit drug-induced vomiting. the elimination of cisapride, how­ high affinity for dopamine recep­ Metoclopramide crosses the blood­ ever, the manufacturer recom­ tors, but low affinity for muscarinic brain barrier and acts at the CTZ mends an initial lower daily and serotonergic receptors. It is a in the area postrema. Although dose4,14,18. Metoclopramide has a peripheral dopamine receptor an­ cisapride also penetrates into the much shorter terminal half-life of tagonist and exhibits many of the CNS, brain tissue concentrations 2.5 to six hours1,15 . In patients with pharmacologic effects of metoclo­ are two or three times less than severely impaired
Load more

Recommended publications
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
    VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction Pathophysiology/Etiology to that observed in dogs. It can be The moving topic of this Vet Talk As with most diseases in the veteri- due to a trichobezoar, dehydration, newsletter will be prokinetic medica- nary world, the etiology and patho- obesity, old age, diabetes, immobility, tions. The availability of information physiology of constipation are varied pain from trauma to the low back, on the many prokinetic agents is var- depending on the species being dis- bladder infection, or an anal sac infec- ied at best so an overall consensus of cussed, where in their gastrointestinal tion. In cases that are more chronic, prokinetic medications will be as- tract the problem is occurring, and underlying disease such as colitis or sessed in this article, hopefully giving any accompanying comorbid condi- Irritable Bowel Syndrome (IBS) may better insight to practitioners about tions. be the culprit. On the other hand, the which agents to use in their patients. cause may be idiopathic which is Canines: In man’s best friend, consti- frustrating for both veterinarian and Prevalence pation has many origins. A dog’s patient since this form is most diffi- Chronic constipation and gastroin- digestive tract itself is complex but cult to treat. testinal stasis are highly debilitating ultimately the mass movements and conditions that not only affect human haustral contractions from the large Equines: Despite their large size, patients but our four legged patients intestine (colon), propel feces into the horses have incredibly delicate diges- as well! Though this condition is rectum stimulating the internal anal tive systems.
    [Show full text]
  • The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders
    The Pharmacology of ProkineticAgents IJGE Issue 4 Vol 1 2003 Review Article The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders George Y. Wu, M.D, Ph.D. INTRODUCTION Metoclopramide Normal peristalsis of the gut requires complex, coordinated neural and motor activity. Pharmacologic Category : Gastrointestinal Abnormalities can occur at a number of different Agent. Prokinetic levels, and can be caused by numerous etiologies. This review summarizes current as well as new Symptomatic treatment of diabetic gastric agents that show promise in the treatment of stasis gastrointestinal motility disorders. For these Gastroesophageal reflux e conditions, the most common medications used in s Facilitation of intubation of the small the US are erythromycin, metoclopramide, and U intestine neostigmine (in acute intestinal pseudo- Prevention and/or treatment of nausea and obstruction). A new prokinetic agent, tegaserod, vomiting associated with chemotherapy, has been recently approved, while other serotonin radiation therapy, or post-surgery (1) agonist agents (prucalopride, YM-31636, SK-951, n ML 10302) are currently undergoing clinical o Blocks dopamine receptors in chemoreceptor i t studies. Other prokinetics, such as domperidone, c trigger zone of the CNS (2) A are not yet approved in the US, although are used in f Enhances the response to acetylcholine of o other countries. tissue in the upper GI tract, causing enhanced m s i n motility and accelerated gastric emptying a DELAYED GASTRIC EMPTYING OR h without stimulating gastric, biliary, or c G A S T R O E S O P H A G E A L R E F L U X e pancreatic secretions.
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • 4 Erythromycin As a Gastrointestinal
    PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 16 Number 4 April 2010 Erythromycin as a Gastrointestinal Prokinetic Agent in Infants Marcia L. Buck, Pharm.D., FCCP, FPPAG rokinetic agents have been used for several receptors during gestation and early infancy. P decades in infants with feeding intolerance Tomomasa and colleagues found a four-fold and gastrointestinal dysmotility following increase in antral contractions in six infants gastrointestinal (GI) surgery. The ability to (gestational age 23-31 weeks) given a 0.75 tolerate enteral feeding leads to a decreased mg/kg IV dose of erythromycin, suggesting reliance on parenteral nutrition and less risk for functional motilin receptors on the stomach catheter-related infections or parenteral nutrition- surface.8 Other investigators have replicated associated cholestasis.1,2 Erythromycin is these findings, demonstrating an erythromycin- increasingly being chosen for this use as the induced increase in antral contractility and gut result of concerns over the toxicities associated transit time in patients > 26 weeks gestation.9 with cisapride and metoclopramide. While the results of studies with erythromycin in infants In 2002, Jadcherla and Berseth studied motor have been mixed, there are a growing number activity in the GI tract of 25 premature and term which suggest it may be of benefit. This issue of infants given low-dose enteral erythromycin Pediatric Pharmacotherapy will review the (0.75, 1.5, or 3 mg/kg).10 A dose-dependent results of studies using erythromycin as a motilin-mediated increase in MMC was found prokinetic agent in infants and assess the relative only in infants 32 weeks gestational age and efficacy and safety of this therapy.
    [Show full text]
  • Itopride : a Novel Prokinetic Agent Seema Gupta, V
    JK SCIENCE DRUG REVIEW Itopride : A Novel Prokinetic Agent Seema Gupta, V. Kapoor, B. Kapoor Non-ulcer dyspepsia (NUD), gastro-esophageal reflux back(5). This drug was first developed by Hokuriku disease (GERD), gastritis, diabetic gastroparesis and Seiyaker Co. Ltd. and has been marketed in Japan since functional dyspepsia are commonly encountered Sept. 1995 (6). disorders of gastric motility in clinical practice. Chemistry Prokinetic drugs such as metoclopramide, domperidone, Chemically it is N-[P-[2-[dimethyl cisapride, mosapride etc. are the mainstay of therapy in amino]ethoxyl]benzyl] veratramide hydrochloride. Its these disorders. These drugs are used to relieve symptoms molecular formula is C20H26O4. HCl (6).The chemical such as nausea, vomiting, bloating, belching, heartburn, structure of Itopride hydrochloride is depicted below: epigastric discomfort etc. Prokinetic drugs act by promoting gastric motility, increase gastric emptying, prevent the retention and reflux of gastric contents and thus provide symptomatic relief (1). All the drugs in this group are efficacious with Mechanism of action modest prokinetic activity but the matter of major Itopride has anticholinesterase (AchE) activity as well concern is their side effect profile. The main side effects as dopamine D2 receptor antagonistic activity and is being of metoclopramide are extra pyramidal such as dystonic used for the symptomatic treatment of various reactions and domperidone, though is devoid of extra- gastrointestinal motility disorders (7, 8). pyramidal effects but is associated with galactorrhoea It is well established that M3 receptors exist on the or gynaecomastia (2). Cisapride has the potential to cause smooth muscle layer throughout the gut and acetylcholine QT prolongation on ECG, thus predisposing to cardiac (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M receptors arrhythmias and its use has been restricted by the US 3 (9).
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • CISAPRIDE (Veterinary—Systemic)
    CISAPRIDE (Veterinary—Systemic) There are no human- or veterinary-labeled commercial ELUS,CANDelayed gastric emptying (treatment)EL; or cisapride products in the United States or Canada. ELUS,CANSmall bowel motility disorders (treatment)EL— Although no feline studies are available, the Category: Gastrointestinal emptying adjunct; documented effects of cisapride in healthy dogs and peristaltic stimulant. other animals suggest it may have efficacy in disorders that benefit from stimulation of gastric, Indications small intestinal, or colonic motility and from Note: Cisapride is not specifically approved for shortened transit time in cats (Evidence rating: B- {R-2; 4-7; 21-24} veterinary use. In other USP information 2). monographs, the ELUS and ELCAN designations refer to uses that are not included in U.S. and Canadian Dogs product labeling; however, in this monograph Potentially effective they reflect the lack of commercial product ELUS,CANGastroesophageal reflux (treatment)EL; availability in the countries indicated. See also the ELUS,CANDelayed gastric emptying (treatment)EL; Regulatory Considerations section below in this ELUS,CANSmall bowel motility disorders (treatment)EL; or monograph. US,CAN EL Colonic motility disorders (treatment)EL — Classification as Accepted, Potentially effective, Although no studies of clinical disease states are or Unaccepted is an evaluation of reasonable use available, studies of the effects of cisapride in that considers clinical circumstances, including healthy dogs suggest it may have efficacy in the availability of other therapies. The quality of disorders that benefit from stimulation of gastric, evidence reviewed for an indication is shown by small intestinal, or colonic motility and from the evidence rating. shortened transit time (Evidence rating: B-2 [table 1][table 2][table3]).{R-4-7; 17; 21-24} Cats Accepted Note: There is no evidence that cisapride is effective in ELUS,CAN EL Constipation, chronic (treatment) ; or the treatment of megaesophagus in dogs.
    [Show full text]
  • Prokinetic Therapy for Feed Intolerance in Critical Illness: One Drug Or Two?
    Prokinetic therapy for feed intolerance in critical illness: One drug or two? Nam Q. Nguyen, MBBS (Hons), FRACP; Marianne Chapman, BMBS, FANZCA, FJFICM; Robert J. Fraser, MBBS, FRACP, PhD; Laura K. Bryant, BHSc; Carly Burgstad, BHSc (Hons); Richard H. Holloway, MBBS, FRACP, MD Objective: To compare the efficacy of combination therapy, with combination therapy, compared with erythromycin alone Over the 7 days, patients .(04. ؍ with erythromycin and metoclopramide, to erythromycin alone in (136 ؎ 23 mL vs. 293 ؎ 45 mL, p the treatment of feed intolerance in critically ill patients. treated with combination therapy had greater feeding success, Design: Randomized, controlled, double-blind trial. received more daily calories, and had a lower requirement for Setting: Mixed medical and surgical intensive care unit. postpyloric feeding, compared with erythromycin alone. Tachy- Patients: Seventy-five mechanically ventilated, medical pa- phylaxis occurred in both groups but was less with combination tients with feed intolerance (gastric residual volume >250 mL). therapy. Sedation, higher pretreatment gastric residual volume, Interventions: Patients received either combination therapy and hypoalbuminemia were significantly associated with a poor mg of intravenous erythromycin twice daily ؉ 10 mg response. There was no difference in the length of hospital stay or 200 ;37 ؍ n) of intravenous metoclopramide four times daily) or erythromycin mortality rate between the groups. Watery diarrhea was more mg of intravenous erythromycin twice daily) in 200 ;38 ؍ alone (n (01. ؍ common with combination therapy (20 of 37 vs. 10 of 38, p a prospective, randomized fashion. Gastric feeding was re-com- but was not associated with enteric infections, including Clos- menced and 6-hourly gastric aspirates performed.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]